TWM527766U - Solid soft orally-soluble tablet containing multi-unit carriers - Google Patents
Solid soft orally-soluble tablet containing multi-unit carriers Download PDFInfo
- Publication number
- TWM527766U TWM527766U TW104220125U TW104220125U TWM527766U TW M527766 U TWM527766 U TW M527766U TW 104220125 U TW104220125 U TW 104220125U TW 104220125 U TW104220125 U TW 104220125U TW M527766 U TWM527766 U TW M527766U
- Authority
- TW
- Taiwan
- Prior art keywords
- solid soft
- ingot
- carrier
- core
- solid
- Prior art date
Links
- 239000007787 solid Substances 0.000 title claims abstract description 78
- 239000000969 carrier Substances 0.000 title claims abstract description 12
- 239000007944 soluble tablet Substances 0.000 title abstract 2
- 239000013543 active substance Substances 0.000 claims abstract description 55
- 239000004005 microsphere Substances 0.000 claims description 33
- 238000010521 absorption reaction Methods 0.000 claims description 24
- 238000000576 coating method Methods 0.000 claims description 19
- 235000003599 food sweetener Nutrition 0.000 claims description 17
- 239000003765 sweetening agent Substances 0.000 claims description 17
- 239000011248 coating agent Substances 0.000 claims description 16
- 239000000463 material Substances 0.000 claims description 16
- 238000002844 melting Methods 0.000 claims description 16
- 229920002472 Starch Polymers 0.000 claims description 15
- 239000000872 buffer Substances 0.000 claims description 15
- 210000000214 mouth Anatomy 0.000 claims description 15
- 235000019698 starch Nutrition 0.000 claims description 15
- 239000008187 granular material Substances 0.000 claims description 14
- 239000003795 chemical substances by application Substances 0.000 claims description 13
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 13
- 239000008107 starch Substances 0.000 claims description 13
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 12
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 12
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 12
- 239000007788 liquid Substances 0.000 claims description 12
- 239000000126 substance Substances 0.000 claims description 12
- 150000005846 sugar alcohols Chemical class 0.000 claims description 12
- 108010010803 Gelatin Proteins 0.000 claims description 11
- -1 aminoalkyl ester Chemical class 0.000 claims description 11
- 239000003623 enhancer Substances 0.000 claims description 11
- 239000008273 gelatin Substances 0.000 claims description 11
- 229920000159 gelatin Polymers 0.000 claims description 11
- 235000019322 gelatine Nutrition 0.000 claims description 11
- 235000011852 gelatine desserts Nutrition 0.000 claims description 11
- 229920000642 polymer Polymers 0.000 claims description 11
- 229920001577 copolymer Polymers 0.000 claims description 8
- 239000011859 microparticle Substances 0.000 claims description 7
- 229920001542 oligosaccharide Polymers 0.000 claims description 7
- 150000002482 oligosaccharides Chemical class 0.000 claims description 7
- 210000003296 saliva Anatomy 0.000 claims description 7
- 239000011345 viscous material Substances 0.000 claims description 7
- 150000003904 phospholipids Chemical class 0.000 claims description 6
- 239000006187 pill Substances 0.000 claims description 6
- 241000894006 Bacteria Species 0.000 claims description 5
- 150000004676 glycans Chemical class 0.000 claims description 5
- 239000001814 pectin Substances 0.000 claims description 5
- 235000010987 pectin Nutrition 0.000 claims description 5
- 229920001277 pectin Polymers 0.000 claims description 5
- 229920001282 polysaccharide Polymers 0.000 claims description 5
- 239000005017 polysaccharide Substances 0.000 claims description 5
- 108090000623 proteins and genes Proteins 0.000 claims description 5
- 102000004169 proteins and genes Human genes 0.000 claims description 5
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 4
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 4
- 239000000194 fatty acid Substances 0.000 claims description 4
- 229930195729 fatty acid Natural products 0.000 claims description 4
- 150000004665 fatty acids Chemical class 0.000 claims description 4
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims description 4
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 4
- 239000002502 liposome Substances 0.000 claims description 4
- 229920003145 methacrylic acid copolymer Polymers 0.000 claims description 4
- 210000003097 mucus Anatomy 0.000 claims description 4
- 229920001661 Chitosan Polymers 0.000 claims description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 3
- 229920001184 polypeptide Polymers 0.000 claims description 3
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 3
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 3
- 239000004094 surface-active agent Substances 0.000 claims description 3
- AXTGDCSMTYGJND-UHFFFAOYSA-N 1-dodecylazepan-2-one Chemical compound CCCCCCCCCCCCN1CCCCCC1=O AXTGDCSMTYGJND-UHFFFAOYSA-N 0.000 claims description 2
- 235000010643 Leucaena leucocephala Nutrition 0.000 claims description 2
- CERQOIWHTDAKMF-UHFFFAOYSA-M Methacrylate Chemical compound CC(=C)C([O-])=O CERQOIWHTDAKMF-UHFFFAOYSA-M 0.000 claims description 2
- MXXWOMGUGJBKIW-YPCIICBESA-N piperine Chemical compound C=1C=C2OCOC2=CC=1/C=C/C=C/C(=O)N1CCCCC1 MXXWOMGUGJBKIW-YPCIICBESA-N 0.000 claims description 2
- 229940075559 piperine Drugs 0.000 claims description 2
- WVWHRXVVAYXKDE-UHFFFAOYSA-N piperine Natural products O=C(C=CC=Cc1ccc2OCOc2c1)C3CCCCN3 WVWHRXVVAYXKDE-UHFFFAOYSA-N 0.000 claims description 2
- 235000019100 piperine Nutrition 0.000 claims description 2
- 241000220479 Acacia Species 0.000 claims 1
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 claims 1
- 239000003826 tablet Substances 0.000 abstract description 5
- 230000004071 biological effect Effects 0.000 abstract 1
- 239000011344 liquid material Substances 0.000 abstract 1
- 239000011162 core material Substances 0.000 description 32
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 30
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 26
- 229930003471 Vitamin B2 Natural products 0.000 description 26
- 229960002477 riboflavin Drugs 0.000 description 26
- 235000019164 vitamin B2 Nutrition 0.000 description 26
- 239000011716 vitamin B2 Substances 0.000 description 26
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 21
- 239000011149 active material Substances 0.000 description 16
- 239000000843 powder Substances 0.000 description 16
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 15
- 229930003268 Vitamin C Natural products 0.000 description 15
- 235000019154 vitamin C Nutrition 0.000 description 15
- 239000011718 vitamin C Substances 0.000 description 15
- 238000000034 method Methods 0.000 description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 14
- 239000000203 mixture Substances 0.000 description 13
- 235000019640 taste Nutrition 0.000 description 13
- 239000003814 drug Substances 0.000 description 12
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 11
- 229940079593 drug Drugs 0.000 description 11
- 230000000694 effects Effects 0.000 description 11
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 11
- 238000002360 preparation method Methods 0.000 description 11
- 229940032147 starch Drugs 0.000 description 11
- 239000002253 acid Substances 0.000 description 10
- 239000002775 capsule Substances 0.000 description 10
- 239000000796 flavoring agent Substances 0.000 description 10
- 238000004519 manufacturing process Methods 0.000 description 10
- 239000008108 microcrystalline cellulose Substances 0.000 description 10
- 229940016286 microcrystalline cellulose Drugs 0.000 description 10
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 9
- 239000010410 layer Substances 0.000 description 9
- 230000001055 chewing effect Effects 0.000 description 8
- 239000000701 coagulant Substances 0.000 description 8
- 239000002994 raw material Substances 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 239000000284 extract Substances 0.000 description 7
- 235000019634 flavors Nutrition 0.000 description 7
- 238000003860 storage Methods 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 6
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 6
- 229930006000 Sucrose Natural products 0.000 description 6
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 6
- 239000002552 dosage form Substances 0.000 description 6
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 6
- 239000008101 lactose Substances 0.000 description 6
- KBPHJBAIARWVSC-RGZFRNHPSA-N lutein Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\[C@H]1C(C)=C[C@H](O)CC1(C)C KBPHJBAIARWVSC-RGZFRNHPSA-N 0.000 description 6
- 210000002200 mouth mucosa Anatomy 0.000 description 6
- 239000003921 oil Substances 0.000 description 6
- 235000019198 oils Nutrition 0.000 description 6
- 239000002356 single layer Substances 0.000 description 6
- 239000005720 sucrose Substances 0.000 description 6
- 235000000346 sugar Nutrition 0.000 description 6
- 210000002700 urine Anatomy 0.000 description 6
- 239000004376 Sucralose Substances 0.000 description 5
- 239000000654 additive Substances 0.000 description 5
- 235000019218 bitter orange extract Nutrition 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000000845 maltitol Substances 0.000 description 5
- 235000010449 maltitol Nutrition 0.000 description 5
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 5
- 229940035436 maltitol Drugs 0.000 description 5
- 238000002156 mixing Methods 0.000 description 5
- 235000019645 odor Nutrition 0.000 description 5
- UPSDNROURFJOQW-UHFFFAOYSA-N phenyl(sulfido)phosphanium Chemical compound C1(=CC=CC=C1)[PH2]=S UPSDNROURFJOQW-UHFFFAOYSA-N 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 235000019408 sucralose Nutrition 0.000 description 5
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 description 5
- 239000006188 syrup Substances 0.000 description 5
- 235000020357 syrup Nutrition 0.000 description 5
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- 229920000084 Gum arabic Polymers 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- JZRWCGZRTZMZEH-UHFFFAOYSA-N Thiamine Natural products CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 description 4
- 235000010489 acacia gum Nutrition 0.000 description 4
- 239000000205 acacia gum Substances 0.000 description 4
- 229910052799 carbon Inorganic materials 0.000 description 4
- 235000010980 cellulose Nutrition 0.000 description 4
- 229920002678 cellulose Polymers 0.000 description 4
- 239000001913 cellulose Substances 0.000 description 4
- 235000009508 confectionery Nutrition 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 235000015110 jellies Nutrition 0.000 description 4
- 239000008274 jelly Substances 0.000 description 4
- 239000011159 matrix material Substances 0.000 description 4
- 125000005395 methacrylic acid group Chemical group 0.000 description 4
- 150000002772 monosaccharides Chemical class 0.000 description 4
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 4
- 238000009495 sugar coating Methods 0.000 description 4
- 235000019157 thiamine Nutrition 0.000 description 4
- 229960003495 thiamine Drugs 0.000 description 4
- KYMBYSLLVAOCFI-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SCN1CC1=CN=C(C)N=C1N KYMBYSLLVAOCFI-UHFFFAOYSA-N 0.000 description 4
- 239000011721 thiamine Substances 0.000 description 4
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 3
- 244000215068 Acacia senegal Species 0.000 description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 3
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 3
- 208000019505 Deglutition disease Diseases 0.000 description 3
- 229930195725 Mannitol Natural products 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 3
- 235000019606 astringent taste Nutrition 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 235000019658 bitter taste Nutrition 0.000 description 3
- 235000015165 citric acid Nutrition 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 238000013270 controlled release Methods 0.000 description 3
- 150000002016 disaccharides Chemical class 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 239000007888 film coating Substances 0.000 description 3
- 238000009501 film coating Methods 0.000 description 3
- 235000013355 food flavoring agent Nutrition 0.000 description 3
- 239000000174 gluconic acid Substances 0.000 description 3
- 235000012208 gluconic acid Nutrition 0.000 description 3
- 239000003292 glue Substances 0.000 description 3
- 125000005456 glyceride group Chemical group 0.000 description 3
- 239000004310 lactic acid Substances 0.000 description 3
- 235000014655 lactic acid Nutrition 0.000 description 3
- 239000001630 malic acid Substances 0.000 description 3
- 235000011090 malic acid Nutrition 0.000 description 3
- 239000000594 mannitol Substances 0.000 description 3
- 235000010355 mannitol Nutrition 0.000 description 3
- 210000003470 mitochondria Anatomy 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- 239000006186 oral dosage form Substances 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- RPGWZZNNEUHDAQ-UHFFFAOYSA-N phenylphosphine Chemical compound PC1=CC=CC=C1 RPGWZZNNEUHDAQ-UHFFFAOYSA-N 0.000 description 3
- 239000011148 porous material Substances 0.000 description 3
- 238000001179 sorption measurement Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- KBPHJBAIARWVSC-XQIHNALSSA-N trans-lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C KBPHJBAIARWVSC-XQIHNALSSA-N 0.000 description 3
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 2
- 240000004160 Capsicum annuum Species 0.000 description 2
- 235000008534 Capsicum annuum var annuum Nutrition 0.000 description 2
- 244000223760 Cinnamomum zeylanicum Species 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 2
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 2
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 2
- 240000003183 Manihot esculenta Species 0.000 description 2
- 235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
- 238000003723 Smelting Methods 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 2
- 229930003270 Vitamin B Natural products 0.000 description 2
- 244000273928 Zingiber officinale Species 0.000 description 2
- 235000006886 Zingiber officinale Nutrition 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- IAJILQKETJEXLJ-QTBDOELSSA-N aldehydo-D-glucuronic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-QTBDOELSSA-N 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 239000002269 analeptic agent Substances 0.000 description 2
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 2
- BTNNPSLJPBRMLZ-LGMDPLHJSA-N benfotiamine Chemical compound C=1C=CC=CC=1C(=O)SC(/CCOP(O)(O)=O)=C(/C)N(C=O)CC1=CN=C(C)N=C1N BTNNPSLJPBRMLZ-LGMDPLHJSA-N 0.000 description 2
- 229960002873 benfotiamine Drugs 0.000 description 2
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 2
- 239000001511 capsicum annuum Substances 0.000 description 2
- 235000017803 cinnamon Nutrition 0.000 description 2
- 239000010630 cinnamon oil Substances 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 230000006835 compression Effects 0.000 description 2
- 238000007906 compression Methods 0.000 description 2
- 239000002826 coolant Substances 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 239000003651 drinking water Substances 0.000 description 2
- 235000020188 drinking water Nutrition 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 2
- 235000008397 ginger Nutrition 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 229940097043 glucuronic acid Drugs 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 2
- 235000021539 instant coffee Nutrition 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 238000003475 lamination Methods 0.000 description 2
- 235000012680 lutein Nutrition 0.000 description 2
- 229960005375 lutein Drugs 0.000 description 2
- 239000001656 lutein Substances 0.000 description 2
- ORAKUVXRZWMARG-WZLJTJAWSA-N lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C ORAKUVXRZWMARG-WZLJTJAWSA-N 0.000 description 2
- 239000001525 mentha piperita l. herb oil Substances 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 2
- 210000004877 mucosa Anatomy 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 2
- 230000035515 penetration Effects 0.000 description 2
- 235000019477 peppermint oil Nutrition 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 235000011007 phosphoric acid Nutrition 0.000 description 2
- 229920000747 poly(lactic acid) Polymers 0.000 description 2
- 229920001592 potato starch Polymers 0.000 description 2
- 229940100486 rice starch Drugs 0.000 description 2
- 229960004889 salicylic acid Drugs 0.000 description 2
- 210000000813 small intestine Anatomy 0.000 description 2
- 229940079832 sodium starch glycolate Drugs 0.000 description 2
- 229920003109 sodium starch glycolate Polymers 0.000 description 2
- 239000008109 sodium starch glycolate Substances 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 229960002920 sorbitol Drugs 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000011975 tartaric acid Substances 0.000 description 2
- 235000002906 tartaric acid Nutrition 0.000 description 2
- 235000019156 vitamin B Nutrition 0.000 description 2
- 239000011720 vitamin B Substances 0.000 description 2
- 239000009637 wintergreen oil Substances 0.000 description 2
- FJHBOVDFOQMZRV-XQIHNALSSA-N xanthophyll Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C=C(C)C(O)CC2(C)C FJHBOVDFOQMZRV-XQIHNALSSA-N 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- FYGDTMLNYKFZSV-URKRLVJHSA-N (2s,3r,4s,5s,6r)-2-[(2r,4r,5r,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5r,6s)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1[C@@H](CO)O[C@@H](OC2[C@H](O[C@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-URKRLVJHSA-N 0.000 description 1
- JKQXZKUSFCKOGQ-JLGXGRJMSA-N (3R,3'R)-beta,beta-carotene-3,3'-diol Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C[C@@H](O)CC1(C)C JKQXZKUSFCKOGQ-JLGXGRJMSA-N 0.000 description 1
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- MIDXCONKKJTLDX-UHFFFAOYSA-N 3,5-dimethylcyclopentane-1,2-dione Chemical group CC1CC(C)C(=O)C1=O MIDXCONKKJTLDX-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- GJCOSYZMQJWQCA-UHFFFAOYSA-N 9H-xanthene Chemical compound C1=CC=C2CC3=CC=CC=C3OC2=C1 GJCOSYZMQJWQCA-UHFFFAOYSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 229920002498 Beta-glucan Polymers 0.000 description 1
- 235000004936 Bromus mango Nutrition 0.000 description 1
- 235000002566 Capsicum Nutrition 0.000 description 1
- 240000008886 Ceratonia siliqua Species 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 102000016942 Elastin Human genes 0.000 description 1
- 108010014258 Elastin Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 239000000940 FEMA 2235 Substances 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- 244000017020 Ipomoea batatas Species 0.000 description 1
- 235000002678 Ipomoea batatas Nutrition 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 240000007228 Mangifera indica Species 0.000 description 1
- 235000014826 Mangifera indica Nutrition 0.000 description 1
- 235000006679 Mentha X verticillata Nutrition 0.000 description 1
- 235000002899 Mentha suaveolens Nutrition 0.000 description 1
- 235000001636 Mentha x rotundifolia Nutrition 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 239000006002 Pepper Substances 0.000 description 1
- 235000016761 Piper aduncum Nutrition 0.000 description 1
- 240000003889 Piper guineense Species 0.000 description 1
- 235000017804 Piper guineense Nutrition 0.000 description 1
- 235000008184 Piper nigrum Nutrition 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 235000009184 Spondias indica Nutrition 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- 229920001938 Vegetable gum Polymers 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- JKQXZKUSFCKOGQ-LQFQNGICSA-N Z-zeaxanthin Natural products C([C@H](O)CC=1C)C(C)(C)C=1C=CC(C)=CC=CC(C)=CC=CC=C(C)C=CC=C(C)C=CC1=C(C)C[C@@H](O)CC1(C)C JKQXZKUSFCKOGQ-LQFQNGICSA-N 0.000 description 1
- QOPRSMDTRDMBNK-RNUUUQFGSA-N Zeaxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCC(O)C1(C)C)C=CC=C(/C)C=CC2=C(C)CC(O)CC2(C)C QOPRSMDTRDMBNK-RNUUUQFGSA-N 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 229940023476 agar Drugs 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 125000003158 alcohol group Chemical group 0.000 description 1
- 125000003172 aldehyde group Chemical group 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- JKQXZKUSFCKOGQ-LOFNIBRQSA-N all-trans-Zeaxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2=C(C)CC(O)CC2(C)C JKQXZKUSFCKOGQ-LOFNIBRQSA-N 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- FYGDTMLNYKFZSV-DZOUCCHMSA-N alpha-D-Glcp-(1->4)-alpha-D-Glcp-(1->4)-D-Glcp Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)O[C@H](O[C@@H]2[C@H](OC(O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-DZOUCCHMSA-N 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229920003144 amino alkyl methacrylate copolymer Polymers 0.000 description 1
- 239000003945 anionic surfactant Substances 0.000 description 1
- 235000010208 anthocyanin Nutrition 0.000 description 1
- 239000004410 anthocyanin Substances 0.000 description 1
- 229930002877 anthocyanin Natural products 0.000 description 1
- 150000004636 anthocyanins Chemical class 0.000 description 1
- 239000002830 appetite depressant Substances 0.000 description 1
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 1
- 239000007961 artificial flavoring substance Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000005178 buccal mucosa Anatomy 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- JUNWLZAGQLJVLR-UHFFFAOYSA-J calcium diphosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])(=O)OP([O-])([O-])=O JUNWLZAGQLJVLR-UHFFFAOYSA-J 0.000 description 1
- 229940043256 calcium pyrophosphate Drugs 0.000 description 1
- 235000019577 caloric intake Nutrition 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 235000013736 caramel Nutrition 0.000 description 1
- 229960004203 carnitine Drugs 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 239000003093 cationic surfactant Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000007910 chewable tablet Substances 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 238000009535 clinical urine test Methods 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 229920000891 common polymer Polymers 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 235000019221 dark chocolate Nutrition 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 235000019821 dicalcium diphosphate Nutrition 0.000 description 1
- 235000013325 dietary fiber Nutrition 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 102000038379 digestive enzymes Human genes 0.000 description 1
- 108091007734 digestive enzymes Proteins 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 235000018927 edible plant Nutrition 0.000 description 1
- 210000004177 elastic tissue Anatomy 0.000 description 1
- 229920002549 elastin Polymers 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 239000010696 ester oil Substances 0.000 description 1
- 235000019441 ethanol Nutrition 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000001125 extrusion Methods 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000010419 fine particle Substances 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- FTSSQIKWUOOEGC-RULYVFMPSA-N fructooligosaccharide Chemical compound OC[C@H]1O[C@@](CO)(OC[C@@]2(OC[C@@]3(OC[C@@]4(OC[C@@]5(OC[C@@]6(OC[C@@]7(OC[C@@]8(OC[C@@]9(OC[C@@]%10(OC[C@@]%11(O[C@H]%12O[C@H](CO)[C@@H](O)[C@H](O)[C@H]%12O)O[C@H](CO)[C@@H](O)[C@@H]%11O)O[C@H](CO)[C@@H](O)[C@@H]%10O)O[C@H](CO)[C@@H](O)[C@@H]9O)O[C@H](CO)[C@@H](O)[C@@H]8O)O[C@H](CO)[C@@H](O)[C@@H]7O)O[C@H](CO)[C@@H](O)[C@@H]6O)O[C@H](CO)[C@@H](O)[C@@H]5O)O[C@H](CO)[C@@H](O)[C@@H]4O)O[C@H](CO)[C@@H](O)[C@@H]3O)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@@H](O)[C@@H]1O FTSSQIKWUOOEGC-RULYVFMPSA-N 0.000 description 1
- 229940107187 fructooligosaccharide Drugs 0.000 description 1
- 239000008369 fruit flavor Substances 0.000 description 1
- 235000021255 galacto-oligosaccharides Nutrition 0.000 description 1
- 150000003271 galactooligosaccharides Chemical class 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 210000004211 gastric acid Anatomy 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000004051 gastric juice Anatomy 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 229940087603 grape seed extract Drugs 0.000 description 1
- 235000002532 grape seed extract Nutrition 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 239000012676 herbal extract Substances 0.000 description 1
- 125000002951 idosyl group Chemical class C1([C@@H](O)[C@H](O)[C@@H](O)[C@H](O1)CO)* 0.000 description 1
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000008776 intercellular pathway Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000006317 isomerization reaction Methods 0.000 description 1
- 210000004731 jugular vein Anatomy 0.000 description 1
- 125000000468 ketone group Chemical group 0.000 description 1
- 239000000832 lactitol Substances 0.000 description 1
- 235000010448 lactitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-JVCRWLNRSA-N lactitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-JVCRWLNRSA-N 0.000 description 1
- 229960003451 lactitol Drugs 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 229940117841 methacrylic acid copolymer Drugs 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 230000004677 mucosal permeability Effects 0.000 description 1
- 239000005445 natural material Substances 0.000 description 1
- 210000005179 oral vestibule Anatomy 0.000 description 1
- 239000006191 orally-disintegrating tablet Substances 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 1
- 238000006552 photochemical reaction Methods 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 229910000028 potassium bicarbonate Inorganic materials 0.000 description 1
- 235000015497 potassium bicarbonate Nutrition 0.000 description 1
- 239000011736 potassium bicarbonate Substances 0.000 description 1
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 1
- 239000006041 probiotic Substances 0.000 description 1
- 235000018291 probiotics Nutrition 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 150000004671 saturated fatty acids Chemical class 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 235000019615 sensations Nutrition 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 239000006104 solid solution Substances 0.000 description 1
- 239000002195 soluble material Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 235000019614 sour taste Nutrition 0.000 description 1
- 238000005563 spheronization Methods 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000000021 stimulant Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 230000009747 swallowing Effects 0.000 description 1
- 230000001839 systemic circulation Effects 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 210000002620 vena cava superior Anatomy 0.000 description 1
- 239000001717 vitis vinifera seed extract Substances 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 235000010930 zeaxanthin Nutrition 0.000 description 1
- 239000001775 zeaxanthin Substances 0.000 description 1
- 229940043269 zeaxanthin Drugs 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
Abstract
Description
本新型是有關於一種口服劑型,且特別是有關於一種固態軟式口服劑型。 The present invention relates to an oral dosage form, and in particular to a solid soft oral dosage form.
隨著製劑技術的進步,目前藥學上的製劑種類越來越多樣,從固態的錠劑到液態的藥液,從速溶劑型到各種控制釋放的劑型,都可以依據所需的藥物作用來做不同的設計。但是,許多藥物都具有令人不悅的味道,因此對於老人與小孩來說,服用藥物常成為一種負擔。 With the advancement of preparation technology, the types of pharmaceutical preparations are becoming more and more diverse, from solid tablets to liquid medicines, from solvent-based to various controlled release dosage forms, which can be different depending on the desired drug action. the design of. However, many drugs have an unpleasant taste, so taking drugs is often a burden for the elderly and children.
膠囊最初是用來做為充填藥物之劑型,可定量粉狀或液狀藥物的服用單位,並且可避免藥物不愉快的味覺。但是,吞食膠囊對許多吞嚥障礙族群,如幼兒、兒童、老人、慢性病患者及癌症患者,也成為一個負擔。 The capsule is initially used as a dosage form for filling a drug, which can be used to quantify the dosage unit of the powdered or liquid drug, and can avoid the unpleasant taste of the drug. However, swallowing capsules has also become a burden for many swallowing disorders such as young children, children, the elderly, chronically ill patients and cancer patients.
為了方便吞嚥障礙族群攝取一些具有藥理 或生物活性的活性物質或營養素,可在口腔中咀嚼之劑型是一種可嘗試的方向。下面提供一種含多單位載體的固態軟式口溶錠,咀嚼後,固態軟式口溶錠會在口腔中崩散或溶解,並釋出載體所攜帶的活性物質或營養素,以利身體吸收活性物質或營養素。 In order to facilitate the swallowing disorder, the group has some pharmacological effects. Or a bioactive active substance or nutrient, a dosage form that can be chewed in the mouth is an attemptable direction. The following provides a solid soft-melt ingot containing a multi-unit carrier. After chewing, the solid soft-melt ingot will disintegrate or dissolve in the oral cavity, and release the active substance or nutrient carried by the carrier, so as to facilitate the body to absorb the active substance or Nutrients.
因此,本新型之一方面是在提供一種含多單位載體的固態軟式口溶錠。上述之固態軟式口溶錠包含核心、外殼和多個載體。其中外殼包覆在核心之外,載體則分布在核心、外殼或上述二者之中。上述之核心的主要材料為糖醇、食用膠質或食用澱粉,核心所用的甜味劑為寡醣或糖醇。上述之載體是用來攜帶至少一種活性物質,活性物質為具有生物活性之固態或液態物質。 Accordingly, one aspect of the present invention is to provide a solid, soft, solubilized ingot containing a multi-unit carrier. The solid soft melt ingot described above comprises a core, a shell and a plurality of carriers. Where the outer casing is wrapped outside the core, the carrier is distributed in the core, the outer casing or both. The main material of the above core is sugar alcohol, edible gum or edible starch, and the sweetener used in the core is oligosaccharide or sugar alcohol. The above carrier is used to carry at least one active substance, and the active substance is a biologically active solid or liquid substance.
依據一實施例,上述之載體包括微粒、微球、微脂體、海綿線粒、滴丸或上述之任意組合。 According to an embodiment, the above carrier comprises microparticles, microspheres, liposomes, sponge granules, dropping pills or any combination of the above.
依據一實施例,上述之載體之至少一部分具有包衣。 According to an embodiment, at least a portion of the above described carrier has a coating.
依據一實施例,更包括一高分子位於該些載體之包衣中,該高分子在唾液中形成黏液,以提高活性物質留置在口腔內的時間。 According to an embodiment, a polymer is further included in the coating of the carrier, the polymer forming a mucus in the saliva to increase the time during which the active substance is retained in the oral cavity.
依據一實施例,上述之高分子包括甲基丙烯酸的共聚物、甲基丙烯酸氨烷基酯的共聚物、甲基丙烯酸酯的共聚物、烷基甲基丙烯酸烷基酯的共聚物、羥丙基纖維素、羥丙甲基纖維素或其任意組合。 According to an embodiment, the polymer comprises a copolymer of methacrylic acid, a copolymer of aminoalkyl methacrylate, a copolymer of methacrylate, a copolymer of an alkyl methacrylate, and a hydroxypropane. Cellulose, hydroxypropylmethylcellulose or any combination thereof.
依據一實施例,更包括一吸收促進劑位於該核心、該外殼、該些載體或上述之任意組合之中。 According to an embodiment, an absorption enhancer is further included in the core, the outer casing, the carriers, or any combination thereof.
依據一實施例,上述之吸收促進劑包括界面活性劑、脂肪酸、酒精、氮酮、幾丁聚醣、磷脂質、引赤劑和胡椒鹼或其任意組合。 According to an embodiment, the absorption enhancer comprises a surfactant, a fatty acid, an alcohol, an azone, a chitosan, a phospholipid, a red-lighting agent, and a piperine or any combination thereof.
依據一實施例,上述之脂肪酸包括具有8-20個碳的飽和或不飽和脂肪酸。 According to an embodiment, the fatty acid described above comprises a saturated or unsaturated fatty acid having from 8 to 20 carbons.
依據一實施例,上述之磷脂質類包括卵磷脂。 According to an embodiment, the phospholipids described above comprise lecithin.
依據一實施例,上述之界面活性劑包括陰離子型界面活性劑或陽離子型界面活性劑。 According to an embodiment, the surfactant described above comprises an anionic surfactant or a cationic surfactant.
依據一實施例,上述之引赤劑包括薑粉或其油萃取物、辣椒粉及或油萃取物、肉桂粉、薄荷油、冬綠油或桂皮油。 According to an embodiment, the red-lighting agent comprises ginger powder or an oil extract thereof, paprika powder and or oil extract, cinnamon powder, peppermint oil, wintergreen oil or cinnamon oil.
依據一實施例,更包括一酸鹼緩衝劑位於該核心、該外殼、該些載體或上述之任意組合中。 According to an embodiment, an acid-base buffer is further included in the core, the outer casing, the carriers, or any combination thereof.
依據一實施例,上述之酸鹼緩衝劑包括弱酸型緩衝劑,該弱酸型緩衝劑包括檸檬酸、蘋果酸、酒石酸、磷酸、乳酸、葡萄糖酸、葡萄醛酸、維生素C、醋酸或水楊酸。 According to an embodiment, the acid-base buffer comprises a weak acid buffer comprising citric acid, malic acid, tartaric acid, phosphoric acid, lactic acid, gluconic acid, glucuronic acid, vitamin C, acetic acid or salicylic acid. .
依據一實施例,上述之酸鹼緩衝劑包括弱鹼型緩衝劑,該弱鹼型緩衝劑包括碳酸氫鹽。 According to an embodiment, the acid-base buffer includes a weak base buffer, and the weak base buffer includes hydrogencarbonate.
依據一實施例,更包括一黏性物質位於該載體中。 According to an embodiment, a viscous substance is further included in the carrier.
依據一實施例,上述之黏性物質包括明膠、果膠、阿拉伯膠、澱粉、多醣體、羥丙基甲基纖維素、蛋白質、多肽、死菌或其任意組合。 According to an embodiment, the viscous substance comprises gelatin, pectin, gum arabic, starch, polysaccharide, hydroxypropyl methylcellulose, protein, polypeptide, dead bacteria or any combination thereof.
上述新型內容旨在提供本揭示內容的簡化摘要,以使閱讀者對本揭示內容具備基本的理解。此新型內容並非本揭示內容的完整概述,且其用意並非在指出本新型實施例的重要/關鍵元件或界定本新型的範圍。在參閱下文實施方式後,本新型所屬技術領域中具有通常知識者當可輕易瞭解本新型之基本精神及其他新型目的,以及本新型所採用之技術手段與實施方面。 The above novel content is intended to provide a simplified summary of the disclosure in order to provide a basic understanding of the disclosure. This Summary is not an extensive overview of the disclosure, and is not intended to identify key/critical elements of the novel embodiments or the scope of the invention. The basic spirit and other novel objects of the present invention, as well as the technical means and implementation aspects of the present invention, can be readily understood by those of ordinary skill in the art.
100‧‧‧固態軟式口溶錠 100‧‧‧solid soft ingots
102‧‧‧核心 102‧‧‧ core
104‧‧‧外殼 104‧‧‧Shell
106‧‧‧載體 106‧‧‧ Carrier
為讓本新型之下述和其他目的、特徵、優點與實施例能更明顯易懂,所附附圖之說明如下: 第1圖係依據本新型一實施例之一種含多單位載體之固態軟式口溶錠的剖面結構示意圖。 The following and other objects, features, advantages and embodiments of the present invention will become more apparent and understood. 1 is a schematic cross-sectional view showing a solid soft-melting ingot containing a multi-unit carrier according to an embodiment of the present invention.
如上所述,利用在固態軟式口溶錠中加入多單位的載體來攜帶各種在常溫下為固態或液態的活性物質,讓固態軟式口溶錠的甜味與香味來處理活性物質部分不愉快的味覺,如苦味及澀味等,讓吞嚥障礙族群容易口服各種活性物質。 As described above, by using a multi-unit carrier in a solid soft-melting ingot to carry various active substances which are solid or liquid at normal temperature, the sweetness and aroma of the solid soft-melt ingot are used to treat the unpleasant taste of the active substance. Such as bitterness and astringency, etc., so that people with dysphagia can easily take various active substances.
因此,提供一種含多單位載體的固態軟式口溶錠。在下面的敘述中,將會介紹上述之含多單位載體的固態軟式口溶錠的例示結構與其例示之製造方法。為了容易瞭解所述實施例之故,下面將會提供不少技術細節。當然,並不是所有的實施例皆需要這些技術細節。同時,一些廣為人知之結構或元件,僅會以示意的方式在附圖中繪出,以適當地簡化附圖內容。 Accordingly, a solid state soft-melt ingot containing a multi-unit carrier is provided. In the following description, the above-described exemplary structure of a solid state soft-melt ingot containing a multi-unit carrier and its exemplified manufacturing method will be described. In order to facilitate an understanding of the described embodiments, a number of technical details are provided below. Of course, not all embodiments require these technical details. In the meantime, some well-known structures or elements are only shown in the drawings in a schematic manner to appropriately simplify the drawing.
由於軟糖在咀嚼一段時間後會在口腔中崩散及溶解,甚至若其尺寸夠小的話還可以直接吞服。因此,若是可以在軟糖中加入活性物質,做成固態軟式口溶錠,則可以在咀嚼過程中讓活性物質釋出於唾液中。但是,要如何讓活性物質可以承受固態軟式口溶錠的各種製作條件而不會變質,使用載體是一個可行的解決方案。因此,在此提供一種含有多單位載體的固態軟式口溶錠及其製備方法。 Because the soft candy will collapse and dissolve in the mouth after chewing for a period of time, even if its size is small enough, it can be swallowed directly. Therefore, if the active substance can be added to the soft candy to form a solid soft-mouthed ingot, the active substance can be released into the saliva during the chewing process. However, the use of the carrier is a viable solution for how the active material can withstand the various manufacturing conditions of the solid soft-melting ingot without deterioration. Accordingly, there is provided a solid state soft-melt ingot containing a multi-unit carrier and a process for the preparation thereof.
依據其所用凝固劑的種類、含水量及製程,固態軟式口溶錠大約可分成下述幾種類型:軟式咀嚼錠、軟式速崩錠、果凍軟糖、彈性軟糖和速崩軟糖。其外型可依所需來決定成任何形狀,其中簡單的外型可為錠狀或球狀。 Depending on the type of coagulant used, the water content and the process, solid soft-melt ingots can be classified into the following types: soft chewable tablets, soft fast-disintegrating tablets, jelly jelly, elastic jelly and fast-dissolving soft candy. The shape can be determined into any shape as desired, and the simple shape can be ingot or spherical.
第1圖係依據本新型一實施例之一種含多單位載體之固態軟式口溶錠的剖面結構示意圖。在第1 圖中,固態軟式口溶錠100的外型可為任何所需的形狀,例如球形、方塊型或其他任何所需形狀。固態軟式口溶錠100的結構包括核心102、包圍在核心102表面之外殼104以及用來攜帶各種不同活性物質的載體(multi-unit active carriers)106。上述之載體106可分布在核心102、外殼104或上述兩者之內。 1 is a schematic cross-sectional view showing a solid soft-melting ingot containing a multi-unit carrier according to an embodiment of the present invention. At the 1st In the drawings, the shape of the solid soft-melting ingot 100 can be any desired shape, such as a sphere, a square, or any other desired shape. The structure of the solid soft-melting ingot 100 includes a core 102, a casing 104 surrounding the surface of the core 102, and a multi-unit active carrier 106 for carrying a variety of different active materials. The carrier 106 described above may be distributed within the core 102, the outer casing 104, or both.
上述核心102基本上為一種軟糖,含有甜味劑與用來固定形狀的凝固劑。核心102的含水量為5-30wt%,例如可為10wt%。除了上述的甜味劑之外,還可以加入做為矯味劑之其他各種不同的酸味劑、香料及味覺刺激劑等等。另外,還可以添加吸收促進劑,以增加活性物質的口腔吸收量。此外,也可以添加弱酸型的酸鹼緩衝劑,讓某些活性物質的分子處於電中性之分子態或自由態(free form)之下,以助其可穿透口腔黏膜,經由細胞內(intracellular)或細胞間(intercellular)的途徑而被吸收。 The core 102 described above is essentially a soft candy containing a sweetener and a coagulant for fixing the shape. The core 102 has a water content of 5 to 30% by weight, for example, 10% by weight. In addition to the above sweeteners, various other sour agents, flavoring and taste stimulating agents, etc., which are flavoring agents, may be added. In addition, an absorption enhancer may also be added to increase the amount of oral absorption of the active substance. In addition, a weak acid type acid-base buffer may be added to allow molecules of certain active substances to be in an electrically neutral molecular state or free form to help penetrate the oral mucosa via the intracellular ( Intracellular) or intercellular pathways are absorbed.
上述之外殼104可為單層或多層的結構,可由核心102乾燥後自然形成外殼104,或是讓核心102另外包裹糖衣、膜衣或其組合而成外殼104。因此外殼104的材料包括矯味劑,如甜味劑、酸味劑、香料及味覺刺激劑。此外,也可選擇性地在外殼104中加入吸收促進劑以及弱酸型的酸鹼緩衝劑。由於固態軟式口溶錠的核心102含水量較高,所以外殼104可以避免核心102彼此黏結在一起,還可以穩定核心102的含 水量,避免核心102變硬。此外,若外殼104具有各種不透明的顏色,還可以幫位於核心102內的活性物質遮光,避免產生光化學反應。此外,各種顏色的外殼104還可提供較令人賞心悅目的外觀。 The outer casing 104 may be of a single layer or a plurality of layers, and may be naturally formed by the core 102 after drying, or the core 102 may be additionally wrapped with a sugar coating, a film coating or a combination thereof to form the outer casing 104. Thus the material of the outer shell 104 includes flavoring agents such as sweeteners, sour agents, flavors and taste stimulants. Further, an absorption enhancer and a weak acid type acid-base buffer may be selectively added to the outer casing 104. Since the core 102 of the solid soft-melting ingot has a high water content, the outer casing 104 can prevent the cores 102 from sticking to each other, and can also stabilize the core 102. The amount of water prevents the core 102 from becoming hard. In addition, if the outer casing 104 has various opaque colors, it can also shield the active material located in the core 102 from light to avoid photochemical reactions. In addition, the outer casing 104 of various colors can also provide a more pleasing appearance.
上述載體106含有活性物質,其可包含人工合成、自天然物萃取或由生物轉化之任何可用的具有生物活性的化學物質(如保健食品、營養補充品或藥物)或生物物質(如酵素、胞器或死菌)。因此,在咀嚼固態軟式口溶錠100時,可讓載體106在貼近口腔黏膜的情況下,釋出高濃度的活性物質,進而提高口腔粘膜對活性物質的吸收量。在核心102中,載體106的添加量可高達為95wt%。 The above carrier 106 contains an active substance, which may comprise any available biologically active chemical substance (such as health food, nutritional supplement or medicine) or biological substance (such as an enzyme, a cell) which is artificially synthesized, extracted from a natural substance or converted by a living organism. Or dead bacteria). Therefore, when the solid soft-melted ingot 100 is chewed, the carrier 106 can release a high concentration of the active substance in close proximity to the oral mucosa, thereby increasing the absorption of the active substance by the oral mucosa. In core 102, carrier 106 can be added in an amount up to 95% by weight.
載體106的直徑約為0.03-3,000μm,依據一實施例其可為100-1,000μm。通常,當載體106的直徑小於150μm時,口腔及舌頭之觸覺即難以察覺。當載體106的直徑小於450μm時,在咀嚼時即難以在短時間內被牙齒咬破,因此可以用較長的咀嚼時間來提高口腔傳輸系統之吸收率,使其可慢慢釋放並慢慢吸收活性物質,所以可在較長時間中維持血液中活性物質的穩定濃度。 The carrier 106 has a diameter of from about 0.03 to about 3,000 μm, which may range from 100 to 1,000 μm in accordance with an embodiment. Generally, when the diameter of the carrier 106 is less than 150 μm, the touch of the mouth and the tongue is hard to detect. When the diameter of the carrier 106 is less than 450 μm, it is difficult to be bitten by a tooth in a short time when chewing, so that a longer chewing time can be used to increase the absorption rate of the oral delivery system, so that it can be slowly released and slowly absorbed. The active substance can maintain a stable concentration of the active substance in the blood for a long period of time.
上述活性物質包括中樞型食欲抑制劑,其例如可為非洲芒果萃取物或苦橙萃取物,其中苦橙萃取物還可以改善代謝。上述活性物質例如還可為維他命BI的誘導體,例如苯磷硫胺(benfotiamine)。 The above active substances include central type appetite suppressants, which may be, for example, African mango extract or bitter orange extract, wherein the bitter orange extract may also improve metabolism. The above active substance may, for example, also be an inducer of vitamin B, such as benfotiamine.
此外,載體106還可選擇性地包含吸收促進劑、酸鹼緩衝劑、在唾液中可形成黏液之高分子以及黏性物質。其中,高分子以及黏性物質可以增加活性物質在口腔中停留的時間,以增加各種不同活性物質之口腔吸收率。例如可增加分別屬於生物藥劑學分類系統第一、二及三類(biopharmaceutical classification system I,II and III)之高水溶性且高黏膜穿透率、低水溶性但高黏膜穿透率以及高水溶性但低黏膜穿透率之活性物質的口腔吸收率。 In addition, the carrier 106 may optionally further comprise an absorption enhancer, an acid-base buffer, a polymer capable of forming a mucus in saliva, and a viscous substance. Among them, the polymer and the viscous substance can increase the residence time of the active substance in the oral cavity to increase the oral absorption rate of various active substances. For example, it can increase the high water solubility and high mucosal permeability, low water solubility but high mucosal penetration rate and high water solubility of the biopharmaceutical classification system I, II and III, respectively. Oral absorption rate of active substances with low mucosal penetration rate.
上述之載體106可為任何可以承受固態軟式口溶錠製造過程之溫度與壓力並足以保護活性物質的載體,例如可為符合上述條件之微粒(pellet)、海綿線粒(Spongellet)、微球(microsphere)、滴丸(dropping pill)、微脂體(liposome)或上述之任意組合。 The carrier 106 described above may be any carrier that can withstand the temperature and pressure of the solid soft-melt ingot manufacturing process and is sufficient to protect the active material, for example, pellets, sponges, and microspheres that meet the above conditions. Microsphere), dropping pill, liposome, or any combination of the above.
上述之微粒是一種由活性物質的粉末或液體與賦形劑(excipients)結合而成的微小球體或類球體,其尺寸通常小於2.5mm。微粒一般是用擠出滾圓方式來製備,還可以使用液體層疊法、粉體層疊法或其組合來在核心微粒上包覆具有不同功能之多層物質,甚至在最外層還可再包覆一層或多層的包衣,而達到增加其所攜帶活性物質的穩定度、控制其內含活 性物質的釋放或控制其吸附外界物質的目的。上述包衣的類型可為糖衣或膜衣。 The above microparticles are microspheres or spheroids composed of a powder or a liquid of an active substance combined with excipients, which are usually less than 2.5 mm in size. The microparticles are generally prepared by extrusion spheronization, and the liquid lamination method, the powder lamination method or a combination thereof may be used to coat the core microparticles with a plurality of layers having different functions, and even the outermost layer may be further coated with a layer or Multi-layer coating to increase the stability of the active substance carried by it and control its internal activity The release of a substance or the purpose of its adsorption of foreign substances. The type of the above coating may be a sugar coating or a film coating.
以糖衣來說,糖衣的主要材料例如可為單醣、雙醣、寡醣或糖醇,因此不僅可以改善味覺之外,還可增加微粒的安定性及硬度。 In the case of sugar coating, the main material of the sugar coating may be, for example, a monosaccharide, a disaccharide, an oligosaccharide or a sugar alcohol, so that not only the taste can be improved, but also the stability and hardness of the microparticles can be increased.
以膜衣來說,其類型例如可分為時間控釋型、pH依賴型、防潮濕型、彈力抗壓型、長效型與大腸釋放型。膜衣的材料例如可為高分子,或者是具有5-50個碳的脂肪酸或其酯類。因此,除了可增加微粒的安定性之外,還可以控制膜衣在特定的環境下崩解,讓微粒接觸外在環境,釋放出活性物質。 In the case of a film coat, the types thereof can be, for example, a time-controlled release type, a pH-dependent type, a moisture-proof type, an elastic compression type, a long-acting type, and a large-intestine release type. The material of the film coat may be, for example, a polymer or a fatty acid having 5 to 50 carbons or an ester thereof. Therefore, in addition to increasing the stability of the particles, it is also possible to control the film coat to disintegrate under a specific environment, allowing the particles to contact the external environment and release the active material.
例如,當膜衣為彈力抗壓型時(其材料通常為彈力纖維或彈力蛋白),可幫助抗壓性較小之活性物質(例如活菌、活性蛋白質及多醣體等等),以抵抗固態軟式口溶錠在製作過程與成型時所承受的壓力,而仍然能保持其活性。 For example, when the film coat is elastic compression type (the material is usually elastic fiber or elastin), it can help the less compressive active substances (such as live bacteria, active proteins and polysaccharides, etc.) to resist solid state. The soft mouth-filled ingot is subjected to the pressure during the manufacturing process and molding, while still maintaining its activity.
例如,當膜衣屬於防潮濕型時,也可以保護會對水分敏感而失去活性的活性物質(例如肉鹼等),使活性物質在固態軟式口溶錠的製造過程及儲存期間都可以維持其活性。 For example, when the film coat is moisture-proof, it can also protect active substances (such as carnitine, etc.) which are sensitive to moisture and lose activity, so that the active substance can be maintained during the manufacturing process and storage of the solid soft-melt ingot. active.
例如,當膜衣屬於pH依賴型,例如酸不溶型,則可以保護對pH敏感的活性物質,使活性物質在固態軟式口溶錠製造過程及儲存期間都可以維持其活性。 For example, when the film coat is pH-dependent, such as an acid-insoluble type, the pH-sensitive active material can be protected so that the active material maintains its activity during the manufacturing process and storage of the solid soft-melt ingot.
例如,當膜衣屬於時間控釋型時,其可使用不溶於胃液與腸液的多孔膜衣,利用孔洞數目的多寡來控制活性物質的釋放速率。例如為緩釋劑型時,可降低活性物質在單位時間內所釋放出之苦味、澀味、腥味等不愉快味覺。若為速釋劑型時,則可以較快釋放出活性物質的甜味、酸味、香味之愉悅味覺,使其與具有不愉快味覺的活性物質競爭口腔之味覺。所以利用此機轉,可解決大部分活性物質中之草本萃取物、食品添加物及藥物之天生異味。 For example, when the film coat is of a time-controlled release type, it can use a porous film coat which is insoluble in gastric juice and intestinal juice, and utilizes the number of holes to control the release rate of the active material. For example, when it is a sustained-release dosage form, the unpleasant taste such as bitterness, astringency, astringency, and the like released by the active substance per unit time can be reduced. In the case of an immediate release dosage form, the sweetness, sourness and a pleasant taste of the active substance can be released relatively quickly, competing with the active substance having an unpleasant taste to compete with the taste of the mouth. Therefore, the use of this machine can solve the natural odor of herbal extracts, food additives and drugs in most active substances.
上述之海綿線粒是一種多孔的線狀藥物載體,其製備法一般為讓活性物質與高水溶性物質與適量的水混合並加以擠出成型後,再以各種不同乾燥法來形成具有多孔結構的海綿線粒。因海綿線粒具有多孔結構,所以可以與各種微粒、微脂體與微球形成複合結構。 The above sponge granule is a porous linear drug carrier, which is generally prepared by mixing an active material with a water-soluble substance and an appropriate amount of water and extruding it, and then forming a porous structure by various drying methods. Sponge granules. Since the sponge mitochondria have a porous structure, a composite structure can be formed with various fine particles, microlipids, and microspheres.
海綿線粒之多孔基質的材料通常為纖維素、澱粉、水溶性物質或其組合。上述之纖維素例如可為羥丙甲基纖維素(hydroxypropyl methyl cellulose;HPMC)、羥丙基纖維素(hydroxypropyl cellulose;HPC)、羥乙基纖維素(hydroxyethyl cellulose;HEC)、微晶纖維素(microcrystalline cellulose,MCC)或其任意組合。上述之水溶性物質例如可為胺基酸或糖醇(分子量多小於200D)。由於海綿線粒具有多孔基質,所以可用來吸附與存納液態 或固態的活性物質,例如溶解於液態油中的活性物質(如高純度之葉黃素及玉米黃素之萃取物或添加物等成分)或奈米到次微米之細粉。因此,對於液態或懸浮態的活性物質,海綿線粒的結構可以保護其不會在固態軟式口溶錠製造過程的擠壓動作中流失而留存下來。對於細粉類的固態活性物質,海綿線粒的結構可以維持其在加工後與咀嚼過程中之活性。上述之海綿線粒和微粒一樣,也可以具有各種不同功能的包衣或膜衣,以達到增加活性物質的穩定度、控制活性物質的釋放以及控制吸附外界物質的目的。 The material of the porous matrix of sponge mitochondria is typically cellulose, starch, water soluble materials or combinations thereof. The cellulose mentioned above may be, for example, hydroxypropyl methyl cellulose (HPMC), hydroxypropyl cellulose (HPC), hydroxyethyl cellulose (HEC), microcrystalline cellulose ( Microcrystalline cellulose, MCC) or any combination thereof. The above water-soluble substance may be, for example, an amino acid or a sugar alcohol (having a molecular weight of less than 200 D). Since the sponge granules have a porous matrix, they can be used for adsorption and storage of liquids. Or a solid active substance such as an active substance dissolved in a liquid oil (such as a high-purity lutein and an extract or additive of zeaxanthin) or a fine powder of nanometer to submicron. Therefore, for the active substance in a liquid or suspension state, the structure of the sponge granule can be protected from being lost in the squeezing action of the solid soft-melting ingot manufacturing process. For finely divided solid active materials, the structure of the sponge mitochondria maintains its activity during processing and chewing. The sponge granules described above, like the microparticles, may also have coatings or film coats of various functions to increase the stability of the active substance, control the release of the active substance, and control the adsorption of foreign substances.
上述之微球是一種讓藥物分散在高分子基質中的藥物載體,其尺寸通常為奈米到微米等級,例如小於800μm。常見之高分子基質的材料包括澱粉、白蛋白(albumin)、明膠(gelatin)、幾丁聚醣(chitosan)、聚乳酸(polylactide;PLA)及環聚乳酸(cyclic polylactate;CPL)等等。其製備方法通常是讓活性物質溶解或分散於高分子溶液中,再利用噴霧乾燥的方式形成微球固體。 The microspheres described above are pharmaceutical carriers for dispersing the drug in a polymeric matrix, typically ranging in size from nanometers to micrometers, such as less than 800 microns. Common polymer matrix materials include starch, albumin, gelatin, chitosan, polylactide (PLA), and cyclic polylactate (CPL). The preparation method is generally to dissolve or disperse the active substance in the polymer solution, and then form a microsphere solid by spray drying.
上述之滴丸,係將藥物與賦形劑均勻混合或分散成一液體系統後,再滴入難溶液體中而成形,所以其會在類圓球體的外面形成一層薄膜。因此,滴丸也是一種藥物載體,用來攜帶適合的活性物質。 The above-mentioned dropping pills are formed by uniformly mixing or dispersing a drug and an excipient into a liquid system, and then dropping into a difficult solution to form a film, so that a film is formed on the outer surface of the spherical body. Therefore, dropping pills are also a pharmaceutical carrier for carrying suitable active substances.
上述之微脂體是一種球狀的囊泡結構,其內部可以用來容納藥物。微脂體可以液體形式存在於微 粒、微球或海綿線粒之孔洞中,或是可以透過加工而存在於微球及滴丸的主體內。 The above-mentioned liposome is a spherical vesicle structure which can be used for containing a drug inside. Microlipids can exist in liquid form The pores of the granules, microspheres or sponge granules may be present in the body of the microspheres and the dropping pills by processing.
承上所述,使用載體106來攜帶活性物質並進而應用於固態軟式口溶錠,至少有下述好處。首先,可增加活性物質的釋放期間。舉例來說,當活性物質做成粉劑時的釋放期間一般為小於5分鐘;若做成直徑1mm微粒時,其釋放期間約為10~15分鐘;若做成直徑0.45mm微粒時,其釋放期間約為7.5~10分鐘。 As described above, the use of the carrier 106 to carry the active material and thus to the solid soft-melt ingot has at least the following advantages. First, the release period of the active substance can be increased. For example, when the active material is used as a powder, the release period is generally less than 5 minutes; if the diameter is 1 mm, the release period is about 10 to 15 minutes; if the diameter is 0.45 mm, the release period is It is about 7.5~10 minutes.
其次,載體106可增加具有不穩定化學結構之活性物質的化學結構穩定性。對於化學結構不穩定的活性物質,不論是對氧氣、濕氣、光線、溫度、壓力或其他因素敏感的活性物質,都可以藉由各種不同方式來修飾載體106的各種不同特性,以保護具有各種不同特性的活性物質,讓其在固態軟式口溶錠的製作過程中及儲存期間不會失去活性,而在咀嚼固態軟式口溶錠時發揮其完整的功效。 Second, the carrier 106 can increase the chemical structural stability of the active material having an unstable chemical structure. For active substances with unstable chemical structure, whether active materials sensitive to oxygen, moisture, light, temperature, pressure or other factors, various characteristics of the carrier 106 can be modified in various ways to protect various kinds of materials. The active substances with different characteristics will not lose their activity during the preparation of the solid soft-melting ingot and during storage, and will exert its full effect when chewing the solid soft-melting ingot.
再來,載體106可以用來攜帶不適合放在一起的活性物質。例如,彼此接觸後會進行化學反應而破壞其活性或產生毒性的活性物質,可以用不同的載體106來分別攜帶時,就可以讓其在固態軟式口溶錠的製作過程中及儲存期間彼此不會接觸,從而保持其原有的活性,直至咀嚼固態軟式口溶錠時才發揮其完整的功效。 Again, the carrier 106 can be used to carry active materials that are not suitable for placement together. For example, active substances that undergo a chemical reaction to destroy their activity or produce toxicity after being contacted with each other can be carried by different carriers 106, respectively, so that they can be prevented from each other during the production of the solid soft-melted ingot and during storage. It will be in contact to maintain its original activity until it is fully functional when chewing a solid soft-melt ingot.
上述凝固劑常用的有糖醇、食用澱粉、食用膠質或上述之任意組合。上述之糖醇,例如可為甘露醇(mannitol)。常用的食用澱粉例如有樹薯澱粉(manioc starch)、玉米澱粉(corn starch)、馬鈴薯澱粉(potato starch)和生米澱粉(uncooked rice starch)。常用的食用膠質依來源可分動物膠和植物膠。常見的動物膠有明膠(gelatin)、阿膠(donkey-hide gelatin)和魚膠(fish gelatin)。常見的植物膠有洋菜膠(agar)、鹿角菜膠(carrageenan)、海藻膠(alginate jelly)、阿拉伯膠(Gum arabic)、關華豆膠(guar gum)、纖維素(cellulose)、角豆果(carob fruit)、糯米膠(glutinous rice glue)、β-葡聚醣(β-glucan)、果膠(pectin)、阿拉伯膠(Acacia gum)和黃原膠(xanthan)。 The above coagulants are usually used as sugar alcohols, edible starches, edible gums or any combination of the above. The above sugar alcohol may be, for example, mannitol. Common edible starches are, for example, manioc starch, corn starch, potato starch, and uncooked rice starch. The commonly used edible gum can be divided into animal glue and vegetable glue according to the source. Common animal gums are gelatin, donkey-hide gelatin and fish gelatin. Common plant gums are agar, carrageenan, alginate jelly, gum arabic, guar gum, cellulose, carob Carob fruit, glutinous rice glue, β-glucan, pectin, Acacia gum, and xanthan.
上述的甜味劑例如可為單醣、雙醣、寡醣、糖醇或上述的任意組合。單醣例如可為五碳糖或六碳糖,常見的五碳糖有阿拉伯糖和木糖,常見的六碳糖有艾杜糖、葡萄糖、果糖和半乳糖。雙醣例如可為蔗糖、乳糖、麥芽糖或海藻糖。寡醣通常是由3-9個單醣單元所組成,例如可為果寡醣、低聚半乳糖、聚異麥芽糖、大豆低聚糖或低聚木糖。糖醇通常是糖分子的醛基或酮基被還原成醇基後所形成,例如可為葡萄糖醇、木糖醇、山梨糖醇、麥芽糖醇、赤蘚醇、乳糖醇 或甘露醇。 The above sweetener may be, for example, a monosaccharide, a disaccharide, an oligosaccharide, a sugar alcohol or any combination of the above. The monosaccharide may be, for example, a five-carbon sugar or a six-carbon sugar. The common five-carbon sugars are arabinose and xylose. The common six-carbon sugars include idose, glucose, fructose and galactose. The disaccharide can be, for example, sucrose, lactose, maltose or trehalose. Oligosaccharides usually consist of 3-9 monosaccharide units, such as fructooligosaccharides, galactooligosaccharides, polyisomaltose, soy oligosaccharides or xylooligosaccharides. The sugar alcohol is usually formed by reduction of an aldehyde group or a ketone group of a sugar molecule to an alcohol group, and may be, for example, glucose alcohol, xylitol, sorbitol, maltitol, erythritol, lactitol. Or mannitol.
甜味劑的主要功能為提供固態軟式口溶錠的甜味,部分甜味劑也有協助凝固的作用,而且某些甜味劑也具有其他的生理功能。例如部分寡醣或糖醇具有類似水溶性膳食纖維的功能,可以促進腸胃的健康並幫助繁殖腸內益生菌。而糖醇則可以協助糖尿病患者控制血糖,並協助肥胖患者控制熱量的攝取。 The main function of the sweetener is to provide the sweetness of the solid soft-melted ingot, some sweeteners also have the effect of assisting coagulation, and some sweeteners have other physiological functions. For example, some oligosaccharides or sugar alcohols have functions similar to water-soluble dietary fibers, which can promote the health of the gastrointestinal tract and help to probiotics in the intestine. Sugar alcohols can help diabetics control blood sugar and help obese patients control caloric intake.
除了甜味劑之外的矯味劑,可為任何可用之酸味劑、香料、味覺刺激劑、鹹味劑或其任意組合。酸味劑例如可為檸檬酸、蘋果酸、乳酸、葡萄糖酸等等。香料例如可為各式天然水果香料、可食用植物香料與可食用的人工香料。味覺刺激劑包括涼味劑與引赤劑,其中涼味劑例如可為薄荷,而引赤劑可為薑粉或其油萃取物、辣椒粉或油萃取物、花椒粉或油萃取物、肉桂粉、薄荷油、冬綠油或桂皮油等。鹹味劑可以是食鹽。最常用者例如可為天然果汁或牛奶。 A flavoring agent other than a sweetener may be any usable sour agent, flavor, taste stimulant, salty agent, or any combination thereof. The sour agent may be, for example, citric acid, malic acid, lactic acid, gluconic acid or the like. The flavors can be, for example, various natural fruit flavors, edible plant flavors, and edible artificial flavors. The taste stimulating agent includes a cooling agent and a red-lighting agent, wherein the cooling agent is, for example, mint, and the red-lighting agent may be ginger powder or an oil extract thereof, paprika or oil extract, pepper powder or oil extract, cinnamon powder, Peppermint oil, winter green oil or cinnamon oil. The salty agent can be a salt. The most common ones can be, for example, natural juices or milk.
上述之酸鹼緩衝劑可分為弱酸型與弱鹼型兩類。弱酸型之酸鹼緩衝劑例如可為檸檬酸、蘋果酸、酒石酸、磷酸、乳酸、葡萄糖酸、葡萄醛酸、維生素C、醋酸或水楊酸。弱酸型酸鹼緩衝劑除了可用來控制口腔內的酸鹼值,並提高弱酸型或弱鹼型活性物質之溶解度之外,還可降低對異味(如苦味)的味覺敏感度,以及協助某些活性物質的分子處於電中性的游離態(free from),以利其穿透口腔黏膜而被吸收。弱鹼 型之酸鹼緩衝劑包括碳酸氫鹽,例如碳酸氫鈉或碳酸氫鉀。弱鹼型之酸鹼緩衝劑除了可用來控制口腔內的酸鹼值之外,還可穩定一些活性物質,若是可以產氣,還可以增加活性物質的釋放速率。當固態軟式口溶錠需同時加入弱酸型及弱鹼型緩衝劑時,弱酸型及弱鹼型必須存在於固態軟式口溶錠之不同位置中。最常見情形為弱酸存在於固態軟式口溶錠、多單位載體,弱鹼存在於載體中。 The above acid-base buffers can be classified into two types: weak acid type and weak base type. The weak acid type acid-base buffer may be, for example, citric acid, malic acid, tartaric acid, phosphoric acid, lactic acid, gluconic acid, glucuronic acid, vitamin C, acetic acid or salicylic acid. In addition to controlling the pH of the oral cavity and increasing the solubility of weak acid or weak base actives, the weak acid acid-base buffer can also reduce the taste sensitivity to odors (such as bitterness) and assist certain The molecules of the active substance are in an electrically neutral free state so that they penetrate the oral mucosa and are absorbed. Weak base Types of acid-base buffers include bicarbonates such as sodium bicarbonate or potassium bicarbonate. In addition to being used to control the pH value in the oral cavity, the weak base type acid-base buffer can also stabilize some active substances, and if it can produce gas, it can also increase the release rate of the active substance. When a solid soft-melt ingot is required to be added with both a weak acid type and a weak base type buffer, the weak acid type and the weak base type must be present in different positions of the solid soft-melt ingot. The most common case is the presence of a weak acid in a solid soft-smelting ingot, a multi-unit carrier, and a weak base present in the carrier.
上述在唾液中可形成黏液之高分子主要用於形成載體106之包衣,其材料包括甲基丙烯酸的共聚物(methacrylic acid copolymer)、甲基丙烯酸氨烷基酯的共聚物(aminoalkyl methacrylate copolymer)、甲基丙烯酸酯的共聚物(methacrylate copolymer)、烷基甲基丙烯酸烷基酯的共聚物(alkyl methacrylate copolymer)、羥丙基纖維素(hydroxylpropyl cellulose)、羥丙甲基纖維素(hydroxypropyl methylcellulose)或其任意組合。上述之甲基丙烯酸的共聚物例如可為聚(甲基丙烯酸-共-丙烯酸乙酯)1:1[Poly(methacrylic acid-co-ethyl acrylate)1:1]、聚(甲基丙烯酸-共-甲基丙烯酸甲酯)1:1[Poly(methacylic acid-co-methyl methacrylate)1:1]、聚(甲基丙烯酸-共-甲基丙烯酸甲酯)1:2[Poly(methacylic acid-co-methyl methacrylate)1:2]或聚(丙烯酸甲 酯-共-甲基丙烯酸甲酯-共-甲基丙烯酸)7:3:1[Poly(methyl acrylate-co-methyl methacrylate-co-methacrylic acid)7:3:1]。上述包衣物質,可透過不同的處理包衣步驟,因而形成不同膜衣層或外殼層。 The above-mentioned polymer capable of forming a mucus in saliva is mainly used for forming a coating of the carrier 106, and the material thereof includes a methacrylic acid copolymer and an aminoalkyl methacrylate copolymer. , methacrylate copolymer, alkyl methacrylate copolymer, hydroxypropyl cellulose, hydroxypropyl methylcellulose Or any combination thereof. The above copolymer of methacrylic acid may be, for example, poly(methacrylic acid-co-ethyl acrylate) 1:1 [poly(methacrylic acid-co-ethyl acrylate) 1:1], poly(methacrylic acid-co- Methyl methacrylate) 1:1 [Poly (methacylic acid-co-methyl methacrylate) 1:1], poly(methacrylic acid-co-methyl methacrylate) 1:2 [Poly (methacylic acid-co- Methyl methacrylate) 1:2] or poly (acrylic acid) Ester-co-methyl methacrylate-co-methacrylic acid 7:3:1 [Poly(methyl acrylate-co-methyl methacrylate-co-methacrylic acid) 7:3:1]. The above coating materials can be passed through different processing coating steps to form different film coating layers or outer skin layers.
上述黏性物質例如可為明膠、果膠、阿拉伯膠、澱粉、多醣體、羥丙基甲基纖維素、蛋白質、多肽、死菌或其任意組合。上述之澱粉例如可為玉米澱粉、木薯澱粉、山藥澱粉、番薯澱粉或生米澱粉。多醣體的來源例如可為植物萃取,或是由酵母菌或真菌發酵而得。上述之蛋白質例如可為膠原蛋白或醣蛋白。 The above viscous substance may be, for example, gelatin, pectin, acacia, starch, polysaccharide, hydroxypropylmethylcellulose, protein, polypeptide, dead bacteria or any combination thereof. The above starch may be, for example, corn starch, tapioca starch, yam starch, sweet potato starch or raw rice starch. The source of the polysaccharide may be, for example, plant extraction or fermentation by yeast or fungi. The above protein may be, for example, collagen or glycoprotein.
含多單位載體固態軟式口溶錠核心102的製備方法可用模具法或打錠法。 The preparation method of the solid soft-smelting ingot core 102 containing the multi-unit carrier can be carried out by a mold method or a tableting method.
在模具法中,先進行混料攪拌的步驟,將所需的原料(甜味劑、凝固劑、載體以及其他所需之添加劑)利用攪拌的動作來將其均勻混合在一起。然後進行加熱的步驟,煮成糖漿。接著,在較大的模具中讓糖漿冷卻到一定溫度後,形成固體,再裁切或壓製成適當大小,形成核心102。 In the mold method, the step of mixing the mixture is first carried out, and the desired raw materials (sweetener, coagulant, carrier, and other desired additives) are uniformly mixed together by a stirring action. Then, the step of heating is carried out to boil the syrup. Next, after the syrup is cooled to a certain temperature in a larger mold, a solid is formed, which is then cut or pressed to an appropriate size to form the core 102.
在打錠法中,將所需需原料的乾燥粉末(甜味劑、凝固劑、載體以及其他所需之添加劑)混合均勻,然後利用打錠機進行打錠,再由外部提高其水分 含量,經特定加工程序來形成核心102。 In the tableting method, the dry powder (sweetener, coagulant, carrier, and other required additives) of the desired raw materials are uniformly mixed, and then the tablet is used for ingoting, and then the water is externally raised. The content is formed into a core 102 by a specific processing procedure.
最後,可選擇是否要再裹上內含所需添加劑的糖衣或膜衣,形成外殼104,完成固態軟式口溶錠100的製作。 Finally, it is selected whether or not to wrap the icing or film coat containing the desired additive to form the outer casing 104 to complete the manufacture of the solid soft-melting ingot 100.
在此實施例中,每單位的固態軟式口溶錠的核心重量約為0.55g,大小約為1.0×0.8×0.5mm3的方形微錠。凝固劑為明膠和澱粉的混合物。甜味劑為蔗糖和麥芽糖醇,香料為焦糖香料。載體為重量比8:1:1之苦橙萃取物複方微球、維他命C微球和吸收促進劑微球,所用吸收促進劑為重量比1:1的磷脂質絲氨酸和磷脂質膽鹼的混合物)。 In this embodiment, the solid weight of the solid soft-melted ingot per unit has a core weight of about 0.55 g and a square micro-ingot having a size of about 1.0 x 0.8 x 0.5 mm 3 . The coagulant is a mixture of gelatin and starch. The sweeteners are sucrose and maltitol, and the flavor is a caramel flavor. The carrier is a bitter orange extract compound microsphere, a vitamin C microsphere and an absorption enhancer microsphere having a weight ratio of 8:1:1, and the absorption enhancer used is a mixture of phospholipid serine and phospholipid choline in a weight ratio of 1:1. ).
在此實施例中,製備了幾種不同的外殼。前三種外殼主要為由麥芽糖醇和蔗糖的混合物所形成的包衣。依據其他添加成分不同,可分為下述3種包衣:不添加色素之透明單層包衣、添加焦糖色素的單層包衣、淡粉紅色雙層包衣(第一層添加1wt%之焦磷酸鈣,第二層包衣為含有0.5wt%花青素之葡萄籽萃取物之淡粉紅色包衣)。而第四種外殼為融化之黑巧克力單層包衣。加了外殼之後,固態軟式口溶錠的重量增加量約為0.15g(單層)、0.23g(雙層)及0.18g(巧克力)。此實施例所用的材料列在下面表一中。由上述及表一可知,即使是同樣的核心材料,外殼還是可以 有很多種的變化。 In this embodiment, several different outer casings were prepared. The first three shells are primarily coatings formed from a mixture of maltitol and sucrose. According to other additives, it can be divided into the following three kinds of coatings: transparent single layer coating without adding pigment, single layer coating with caramel color added, light pink double coating (adding 1wt% to the first layer) Calcium pyrophosphate, the second coating is a pale pink coating containing 0.5% by weight of anthocyanin grape seed extract). The fourth shell is a single layer coating of melted dark chocolate. After the outer shell was added, the weight gain of the solid soft-melt ingot was about 0.15 g (single layer), 0.23 g (double layer), and 0.18 g (chocolate). The materials used in this example are listed in Table 1 below. As can be seen from the above and Table 1, even if the same core material, the outer casing can still There are many variations.
此外,在此實施例中,還改變載體在固態口溶錠核心中的含量,並測試其口感,將所得結果列在下面的表二中。由表二的結果可知,載體的含量越高,固態軟式口溶錠的口感會越鬆軟。 Further, in this example, the content of the carrier in the solid solution core was also changed, and the mouthfeel was tested, and the results obtained are shown in Table 2 below. It can be seen from the results of Table 2 that the higher the content of the carrier, the softer the mouthfeel of the solid soft-melted ingot.
*吸收促進劑的成分為重量比1:1的磷脂質絲氨酸和磷脂質膽鹼 *The composition of the absorption enhancer is phospholipid serine and phosphatidylcholine in a weight ratio of 1:1.
在此實施例中,將凝固劑改為屬於植物膠的果膠和阿拉伯膠的混合物,取代傳統使用的明膠,讓核心成形。固態軟式口溶錠的核心大小約為1.0×0.8×0.5mm3之方形,重量約為1.0g。所用之載體為苦橙萃取物複方微球,添加量為10wt%。外殼主要為由麥芽糖醇和蔗糖的混合物所形成的單層包衣。此實施例所用的材料列在下面表三中。 In this embodiment, the coagulant is changed to a mixture of pectin and gum arabic belonging to vegetable gum, and the core is shaped by replacing the gelatin which is conventionally used. The solid soft-melting ingot has a core size of about 1.0 x 0.8 x 0.5 mm 3 square and a weight of about 1.0 g. The carrier used was a bitter orange extract compound microsphere in an amount of 10% by weight. The outer shell is primarily a single layer coating formed from a mixture of maltitol and sucrose. The materials used in this example are listed in Table 3 below.
在此實施例中,各成分請見下面的表四,但是凝固劑改為甘露醇,甜味劑改為糖尿病患者可用之山梨醇、麥芽糖醇、果寡醣與麥芽寡醣。所用之載體為苦橙萃取物複方微球,添加量為10wt%。 In this example, the ingredients are shown in Table 4 below, but the coagulant was changed to mannitol, and the sweetener was changed to sorbitol, maltitol, fructooligosaccharide and malto-oligosaccharide available to diabetic patients. The carrier used was a bitter orange extract compound microsphere in an amount of 10% by weight.
在此實施例中,所用各成分請看下面的表五,其中載體改為重量比8:1:1之苯磷硫胺微球、維他命C微球和吸收促進劑微球。上述之苯磷硫胺微球的成分為重量比70:10:8:1.5:0.5的苯磷硫胺、微晶纖維素、即溶咖啡粉、羥丙甲基纖維素和蔗糖素。而且苯磷硫胺微球還可以再進一步浸於糖水或其他甜味劑的溶液中,讓糖水或甜味劑溶液滲入苯磷硫胺微 球的孔隙中。 In this example, the ingredients used are shown in Table 5 below, in which the carrier was changed to a benzenephosphine thiamine microsphere, a vitamin C microsphere, and an absorption enhancer microsphere having a weight ratio of 8:1:1. The above components of the phenylphosphine sulfide microspheres are phenylphosphine sulfide, microcrystalline cellulose, instant coffee powder, hydroxypropylmethylcellulose and sucralose in a weight ratio of 70:10:8:1.5:0.5. Moreover, the phenylphosphine thiamine microspheres can be further immersed in a solution of syrup or other sweetener to allow the syrup or sweetener solution to penetrate into the phenylphosphine thiamine microsphere. In the pores of the ball.
在此實施例中,用來改善糖尿病患者臨床治療副作用的苯磷硫胺(Benfotiamine),其異味可被苯磷硫胺微球的原料及釋放特性所修飾,再加上固態軟式口溶錠和其核心中所添加的甜味劑與香料,可將苯磷硫胺的異味幾乎完全掩蓋。 In this embodiment, Benfotiamine, which is used to improve the clinical treatment side effects of diabetic patients, has an odor which can be modified by the raw material and release characteristics of the phenylphosphine thiamine microspheres, together with a solid soft-melted ingot and The sweeteners and flavors added to the core can almost completely mask the odor of phenylphosphine sulfide.
*苯磷硫胺微球的成分為重量比70:10:8:1.5:0.5的苯磷硫胺、微晶纖維素、即溶咖啡粉、羥丙甲基纖維素和蔗糖素。 * The composition of the phenylphosphine sulfide microspheres is phenylphosphine sulfide, microcrystalline cellulose, instant coffee powder, hydroxypropylmethylcellulose and sucralose in a weight ratio of 70:10:8:1.5:0.5.
在此實施例中,所用活性物質為20wt%葉黃素酯的油狀溶液,所用材料的詳細內容請見下面的表六。經製備成葉黃素酯微球後,由於其硬度大於7 H,即使經過固態軟式口溶錠的100℃和400Kg/cm2的高溫高壓製程,微球外觀仍然保持良好,足以維持葉黃素酯油狀溶液的安定性。 In this example, the active material used was an oily solution of 20% by weight of lutein ester, and the details of the materials used are shown in Table 6 below. After preparation of lutein ester microspheres, the microspheres remain good enough to maintain lutein even though they have a hardness greater than 7 H, even after 100 ° C and 400 Kg/cm 2 high temperature and high pressure processes of solid soft-melting ingots. The stability of the ester oily solution.
*葉黃素酯微球的成分為重量比30:65:5之葉黃素酯油狀溶液、微晶纖維素和羥丙基甲基纖維素(hydroxylpropyl methyl cellulose;HPMC)。 * The lutein ester microspheres are composed of a lutein ester oil solution, microcrystalline cellulose, and hydroxylpropyl methyl cellulose (HPMC) in a weight ratio of 30:65:5.
維他命B2在酸性有水的環境中,會進行異構化反應,因此會變色並有異味。在此實施例中,實驗組之載體的原料為重量比75:5:20之維他命C、維他命B2和微晶纖維素。對照組則是上述原料的混合物,維他命C、維他命B2和微晶纖維素的重量比也是75:5:20。 Vitamin B2 undergoes an isomerization reaction in an acidic and watery environment, and thus discolors and has an odor. In this example, the starting material of the carrier of the experimental group was vitamin C, vitamin B2 and microcrystalline cellulose in a weight ratio of 75:5:20. The control group was a mixture of the above materials, and the weight ratio of vitamin C, vitamin B2 and microcrystalline cellulose was also 75:5:20.
固態軟式口溶錠的製備方法為取100g之載體或上述原料混合物,分別加入60g明膠、270g蔗 糖和300g水,攪拌並加熱至約100℃,形成均勻的糖漿混合物。在常溫下冷卻至室溫以及乾燥後,再繼續冷藏12小時。取出後,切割成大小為1.0×0.8×0.5cm3的方形,得到固態軟式口溶錠。對照組的原料亦經過相同的製程條件,製成固態軟式口溶錠。在下面表七中列出此實施例所用之各種材料。 The solid soft-mouthed ingot is prepared by taking 100 g of the carrier or the above-mentioned raw material mixture, respectively adding 60 g of gelatin, 270 g of sucrose and 300 g of water, stirring and heating to about 100 ° C to form a uniform syrup mixture. After cooling to room temperature at room temperature and drying, the refrigerating was continued for another 12 hours. After taking out, it was cut into a square having a size of 1.0 × 0.8 × 0.5 cm 3 to obtain a solid soft-melt ingot. The raw materials of the control group were also subjected to the same process conditions to prepare a solid soft-melt ingot. The various materials used in this example are listed in Table 7 below.
在下面表八中,觀察製造過程以及儲存14天後的外觀變化,以瞭解固態軟式口溶錠的製備及儲存穩定性。由表八的結果可知,當維他命B2放入載體中,即使在酸性有水的環境下,也不容易變質,增加其穩定性。 In Table 8 below, the manufacturing process and the change in appearance after 14 days of storage were observed to understand the preparation and storage stability of the solid soft-melted ingot. From the results of Table 8, it can be seen that when the vitamin B2 is placed in a carrier, it is not easily deteriorated even in an acidic water environment, and its stability is increased.
*成分為重量比75:5:20之維他命C、維他命B2和微晶纖維素。 * Ingredients are vitamin C, vitamin B2 and microcrystalline cellulose in a weight ratio of 75:5:20.
在此實施例中,測試幾種不同口腔釋放活性物質的劑型,比較其活性物質在口腔中可持續釋放時間的長短。在此所使用的活性物質為維他命C,所以是測試酸味在口腔中停留的時間長短。測試前先以飲用水漱口,以維持口腔內有足夠及恆定的濕潤度與較恆定的溫度。下面敘述各實驗例所測試之劑型,所得結果列在下表中。 In this embodiment, several different oral release actives are tested and the length of time in which the active is sustained in the oral cavity is compared. The active substance used herein is vitamin C, so it is a test of the length of time that the sour taste stays in the oral cavity. Rinse the drinking water before testing to maintain sufficient and constant humidity and a constant temperature in the mouth. The dosage forms tested in the respective experimental examples are described below, and the results obtained are shown in the following table.
實驗組為含有維他命C及維他命B2之微球的固態軟式口溶錠。微球的原料與上述實施例十一的微球相同。固態軟式口溶錠的其他原料為重量比7:1:1:1的蔗糖、明膠、澱粉和水。固態軟式口溶錠的大小為1.0×0.9×0.6cm3,重量約為0.65g。每顆固態軟式口溶錠含有17wt%的維他命C和1.1wt%的維他命B2。詳細材料請見下面的表九。 The experimental group was a solid soft-mouthed ingot containing microspheres of vitamin C and vitamin B2. The raw material of the microspheres was the same as the microspheres of the above-mentioned Example 11. The other raw materials for the solid soft-melting ingot are sucrose, gelatin, starch and water in a weight ratio of 7:1:1:1. The solid soft-mouthed ingot has a size of 1.0 x 0.9 x 0.6 cm 3 and a weight of about 0.65 g. Each solid soft-melted ingot contains 17% by weight of vitamin C and 1.1% by weight of vitamin B2. See Table 9 below for details.
*成分為重量比75:5:20之維他命C、維他命B2和微晶纖維素。 * Ingredients are vitamin C, vitamin B2 and microcrystalline cellulose in a weight ratio of 75:5:20.
對照組則有下面所述之舌下吸收型膠囊、舌下錠、口崩錠和口含錠。 In the control group, there are sublingual absorption capsules, sublingual ingots, orally disintegrating ingots and buccal ingots as described below.
舌下吸收膠囊的膠囊具有6個直徑約為0.37mm的孔洞,內含物為115mg之乳糖和115mg之維他命C。 The capsule of the sublingual absorption capsule has six pores having a diameter of about 0.37 mm, and the contents are 115 mg of lactose and 115 mg of vitamin C.
舌下錠的直徑約為6mm,其含有115mg之乳糖和115mg之維他命C。 The sublingual ingot has a diameter of about 6 mm and contains 115 mg of lactose and 115 mg of vitamin C.
口崩錠內含有100mg之乳糖、100mg之維他命C和30mg的崩散劑(羥基乙酸澱粉鈉)。 The otoposide contains 100 mg of lactose, 100 mg of vitamin C and 30 mg of disintegrating agent (sodium starch glycolate).
口含錠的直徑約為10mm,其含有115mg之乳糖和115mg之維他命C。 The buccal ingot has a diameter of about 10 mm and contains 115 mg of lactose and 115 mg of vitamin C.
所得結果,如下面表十所示。 The results obtained are shown in Table 10 below.
a 以舌頭觸覺感受製劑消散時間 a with the tongue touch sense agent dissipating time
b 以舌頭觸覺感受製劑消散時間 b with tongue tactile sensation dissipating time
c 部分微粒隨口水吞下 Part c particles swallowed with saliva
在此實施例中,測試幾種不同口腔釋放活性物質的劑型,比較其活性物質的吸收速率及血液中有效濃度維持的時間長短。在此所使用的活性物質為維他命B2,所以可由尿液的顏色得知維他命B在體內停留的時間。 In this embodiment, several different oral release actives are tested, comparing the rate of absorption of the active substance with the length of time during which the effective concentration in the blood is maintained. The active substance used here is vitamin B2, so the time in which the vitamin B stays in the body can be known from the color of the urine.
實驗組為固態軟式口溶錠,其所用載體為維他命B2複方的海綿線粒或微球。每450mg的固態軟式口溶錠含有25mg的維他命B2。 The experimental group was a solid soft oral ingot, and the carrier used was a sponge granule or microsphere of a vitamin B2 compound. Each 450 mg of solid soft-melted ingot contains 25 mg of vitamin B2.
上述維他命B2複方海綿線粒的製備方法如 下所述。先將維他命B2與蔗糖素溶解於60-70℃之甘油酯之中,維他命B2、蔗糖素與甘油酯的重量比為50:5:45,總重為500g。均勻混合後,讓混合物快速冷卻,形成黃色薄塊。所得黃色薄塊以粉碎機粉碎後過40號篩,而得到黃色細粉。接著,讓黃色細粉和甘胺酸混合,黃色細粉和甘胺酸的重量比為3:7。然後用單螺桿擠出機再加入原料總重之10wt%蒸餾水後擠出,置於防潮箱中陰乾約48小時後,形成含維他命B2(15wt%)之海綿線粒。 The preparation method of the above vitamin B2 compound sponge granules is as follows As described below. Vitamin B2 and sucralose were first dissolved in a glyceride at 60-70 ° C. The weight ratio of vitamin B2, sucralose to glyceride was 50:5:45, and the total weight was 500 g. After homogeneous mixing, the mixture was allowed to cool rapidly to form a thin yellow mass. The obtained yellow thin piece was pulverized by a pulverizer and passed through a No. 40 sieve to obtain a yellow fine powder. Next, the yellow fine powder and the glycine acid were mixed, and the weight ratio of the yellow fine powder to the glycine was 3:7. Then, 10 wt% of distilled water was added to the total weight of the raw material by a single-screw extruder, and then extruded, and placed in a moisture-proof box for about 48 hours to form a sponge-containing granule containing vitamin B2 (15 wt%).
上述維他命B2複方微球的製備方法如下所述。將重量比為50:5:40:5之維他命B2、蔗糖素、微晶纖維素、羥丙基甲基纖維素混合,擠出滾圓後乾燥,形成維他命B2複方微球。 The preparation method of the above vitamin B2 compound microspheres is as follows. The vitamin B2, sucralose, microcrystalline cellulose, and hydroxypropyl methylcellulose in a weight ratio of 50:5:40:5 are mixed, squeezed and rounded, and dried to form a vitamin B2 compound microsphere.
對照組為舌下吸收膠囊和口崩錠。舌下吸收膠囊為3號膠囊,具有直徑約為0.67mm的6個孔洞。每個膠囊充填有230mg的維他命B2複方海綿線粒,其中含有25mg的維他命B2。上述口崩錠是由230mg的維他命B2製劑(甘油酯和維他命B2的混合物)、30mg羥基乙酸澱粉鈉及40mg乳糖混合後打錠而成。錠片的直徑為10mm,厚度為2.5mm,硬度約為4 H。 The control group was a sublingual absorption capsule and an orally disintegrating ingot. The sublingual absorption capsule is a No. 3 capsule having six holes having a diameter of about 0.67 mm. Each capsule was filled with 230 mg of vitamin B2 compound sponge granules containing 25 mg of vitamin B2. The above-mentioned orally disintegrating tablet was prepared by mixing 230 mg of a vitamin B2 preparation (a mixture of glyceride and vitamin B2), 30 mg of sodium starch glycolate and 40 mg of lactose. The tablet has a diameter of 10 mm, a thickness of 2.5 mm, and a hardness of about 4 H.
測試方法為讓同一人,在不同五天的上午9時,先喝下300mL飲用水,再分別服用實驗例3-1至3-5的各種口服劑型之維他命B2。接著,在不同時間點(09:00、09:15、09:30、10:30、13:00與 15:00)測試尿液顏色。 The test method is to let the same person drink 300mL of drinking water at 9:00 in the next five days, and then take the vitamin B2 of various oral dosage forms of Experimental Examples 3-1 to 3-5. Then, at different points in time (09:00, 09:15, 09:30, 10:30, 13:00) 15:00) Test urine color.
尿液是以呈色法來比較,呈色法的標準品請見表十一。其中標準品E為未服用維他命B2時之09:00的尿液,而標準品A~D為標準品E再加入不同量的維他命B2所製成。而依據表十一所列標準品的顏色,所得尿液測試結果請見下面的表十二。 The urine is compared by the color method, and the standard of the color method is shown in Table 11. The standard E is 09:00 urine when no vitamin B2 is taken, and the standard A~D is standard E and then added with different amounts of vitamin B2. According to the color of the standard listed in Table 11, the urine test results are shown in Table 12 below.
由上面的表十二的結果可知,服用口崩錠及載體是微球的固態軟式口溶錠者,其尿液在90分鐘才開始變黃,顯示維他命B2多由小腸吸收後,才代謝並經由腎臟排出。而服用舌下吸收膠囊和載體為速溶性海綿線粒的固態軟式口溶錠者,其尿液在15-30分鐘就開始變黃。顯示這兩者是由舌下黏膜吸收,很快就進入循環系統,所以由腎臟排出的速率較快。 From the results of Table 12 above, it can be seen that the oral soft-dissolved ingots and the carrier are microspheres, and the urine begins to turn yellow in 90 minutes, indicating that the vitamin B2 is mostly absorbed by the small intestine before being metabolized. Excreted through the kidneys. In the case of a sublingual absorption capsule and a solid soft-melting ingot of the carrier which is a fast-dissolving sponge granule, the urine starts to yellow in 15-30 minutes. It is shown that both are absorbed by the sublingual mucosa and quickly enter the circulatory system, so the rate of excretion by the kidneys is faster.
由上述可知,溶解於唾液中的活性物質可以局部作用於口腔,或進一步由口腔黏膜(包括雙頰黏膜、舌下黏膜與口腔前庭)吸收。由口腔黏膜吸收活性物質具有如下好處,例如可在5分鐘之內就產生起效作用(onset),可以用較小的服用劑量來達到血液中的有效濃度及最高血中濃度,可以不經過肝臟及小腸的首度代謝就進入全身循環產生藥理作用,可以不用經過胃酸及腸胃道消化酵素的分解與消化而導致去活化作用,以及在吸收後可直接經由頸靜脈等上腔靜脈系統運輸與循環至心臟、腦部、肺臟及皮膚等組織中。 It can be seen from the above that the active substance dissolved in the saliva can be locally applied to the oral cavity or further absorbed by the oral mucosa (including the buccal mucosa, the sublingual mucosa and the oral vestibule). Absorption of the active substance by the oral mucosa has the following advantages, for example, an onset can be produced within 5 minutes, and a small dose can be used to achieve an effective concentration in the blood and a maximum blood concentration, without passing through the liver. And the first metabolism of the small intestine enters the systemic circulation to produce pharmacological effects, which can be deactivated without the decomposition and digestion of gastric acid and gastrointestinal digestive enzymes, and can be transported and circulated directly through the superior vena cava system such as the jugular vein after absorption. To tissues such as the heart, brain, lungs, and skin.
雖然本新型已以實施方式揭露如上,然其並非用以限定本新型,任何熟習此技藝者,在不脫離本新型之精神和範圍內,當可作各種之更動與潤飾,因此本新型之保護範圍當視後附之申請專利範圍所界定者為準。 Although the present invention has been disclosed in the above embodiments, it is not intended to limit the present invention. Any one skilled in the art can make various changes and retouchings without departing from the spirit and scope of the present invention. The scope is subject to the definition of the scope of the patent application attached.
100‧‧‧固態軟式口溶錠 100‧‧‧solid soft ingots
102‧‧‧核心 102‧‧‧ core
104‧‧‧外殼 104‧‧‧Shell
106‧‧‧載體 106‧‧‧ Carrier
Claims (10)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| TW104220125U TWM527766U (en) | 2015-12-15 | 2015-12-15 | Solid soft orally-soluble tablet containing multi-unit carriers |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| TW104220125U TWM527766U (en) | 2015-12-15 | 2015-12-15 | Solid soft orally-soluble tablet containing multi-unit carriers |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TWM527766U true TWM527766U (en) | 2016-09-01 |
Family
ID=57443414
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW104220125U TWM527766U (en) | 2015-12-15 | 2015-12-15 | Solid soft orally-soluble tablet containing multi-unit carriers |
Country Status (1)
| Country | Link |
|---|---|
| TW (1) | TWM527766U (en) |
-
2015
- 2015-12-15 TW TW104220125U patent/TWM527766U/en not_active IP Right Cessation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2009274404B2 (en) | Appetising medicament for oral administration in solid form | |
| CN107613918B (en) | Multi-component fondant composition with hard core | |
| US11896598B2 (en) | Appetite suppressant compositions and methods thereof | |
| KR102671429B1 (en) | Easy-to-take particle composition for solid preparation and easy-to-take solid preparation comprising the particle composition | |
| CN104644609B (en) | A kind of feature masticatory pattern soft capsule skin | |
| US20100266687A1 (en) | Improved tablet coating | |
| JP2016174616A (en) | Disintegrable composition, and easily disintegrable compression molding | |
| CA3074541C (en) | Appetite suppressant compositions and methods thereof | |
| WO2005011402A1 (en) | Masticatable capsule and process for producing the same | |
| KR20210002478A (en) | Easy-to-take granules and manufacturing method thereof | |
| TWI690333B (en) | Manufacturing method of easy-to-take solid preparation (with nuclear ingot) and easy-to-take solid preparation | |
| CN205411710U (en) | Solid soft mouth dissolving ingot containing multi-unit carrier | |
| TWM527766U (en) | Solid soft orally-soluble tablet containing multi-unit carriers | |
| TW201720429A (en) | Solid soft orally-soluble tablet containing multi-unit carriers | |
| CN205597045U (en) | Chewing gum containing multiple active carrier units | |
| CN106880599B (en) | Solid soft oral dissolving tablet containing multi-unit carrier | |
| TWI698181B (en) | Chewing gum containing multi-unit active carriers | |
| US20240115641A1 (en) | Oral film and stick jelly for improving absorption in the oral mucosa, antioxidant activity, anti-inflammatory activity, and liver function of humans and companion animals | |
| KR19990008528A (en) | Chewable body and its manufacturing method | |
| TWM513700U (en) | Chewing gum containing multi-unit active carriers | |
| CN106359822A (en) | Chewing gum containing multiple active carrier units | |
| EP3097906A1 (en) | Pharmaceutical formulation for administration of medicines | |
| HK1147422A (en) | Improved tablet coating |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4K | Annulment or lapse of a utility model due to non-payment of fees |